SAN DIEGO --(BUSINESS WIRE)--Jul. 28, 2020-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020 . Second Quarter 2020 Financial Highlights: Revenue grew 34% versus the same quarter of the prior year to $451.8 million U.S.

TORONTO , July 16, 2020 /CNW/ - Last week, Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring (CGM) system by pregnant women with Type 1, Type 2, or gestational diabetes. This temporary expanded indication was granted because of the active role

SAN DIEGO --(BUSINESS WIRE)--Jun. 30, 2020-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020 . Management will hold a conference call to review the company's second quarter 2020 performance

SAN DIEGO --(BUSINESS WIRE)--Jun. 4, 2020-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference: Steve Pacelli , Executive Vice President, Strategy and Corporate Development, will present on behalf of the company

SAN DIEGO --(BUSINESS WIRE)--May 12, 2020-- DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to

SAN DIEGO --(BUSINESS WIRE)--May 11, 2020-- DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”) in a private placement to

SAN DIEGO --(BUSINESS WIRE)--May 8, 2020-- DexCom, Inc. (NASDAQ:DXCM) today announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom, Inc. (the “Company”) has been changed and will be held as a hybrid meeting that

TORONTO , May 4, 2020 /CNW/ - Health Canada recently announced the Dexcom G6 Continuous Glucose Monitoring (CGM) system has been temporarily authorized for expanded use in hospitals, in an effort to help remotely monitor those who are critically ill during the COVID-19 pandemic.

SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2020-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2020 . First Quarter 2020 and COVID-19 Pandemic Response Highlights: Revenue grew 44% versus the same quarter of the prior year to $405.1 million

SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2020-- DexCom , Inc. ( NASDAQ:DXCM ), the leader in continuous glucose monitoring (CGM) systems for people with diabetes, announced today a new patient assistance program to aid current U.S. customers who have lost insurance due to the COVID-19 pandemic.